Abstract
dc:description.abstractStargardt disease type 1 (STGD1) is the most common autosomal recessive macular dystrophy. There is no available treatment thus far. Mutations in the large ABCA4 gene are the cause behind STGD1. The gene codifies for ABCA4 protein, which is located in the photoreceptors (PR) and is involved in the retinoid cycle. Loss of function of ABCA4 results in toxic lipofuscin deposits in the retinal pigment epithelium (RPE), leading to PR degeneration. Given the limitations of the STGD1 murine model we have developed and characterized two novel swine models, somatic and germline ABCA4 knock out. Both models showed lipofuscin accumulation in the RPE. The germline model showed an enhanced accumulation in the cone-rich streak region in the center of the retina. Reduced cone activity was also found in the older germline knock out swines. We tested in the germline a dual AAV therapeutic strategy based on inteins to induce ABCA4 reconstitution in the PR after subretinal administration. Eyes injected with the dual AAV intein vectors show ABCA4 expression and lower lipofuscin levels compared to buffer injected eyes. Another strategy for disease causing mutation correction is genome editing via CRISPR Cas9 systems. We developed a system relying in non-homologous end-joining (NHEJ) that resulted in a proof-of-concept of efficacy of DNA targeted integration in the abca4 locus in vitro and in the STGD1 murine model.
Degree
thesis:*- Name dc:type.qualificationname
- phd
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- The Open University
- Year dc:date.issued
- 2024
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Pugni, Eugenio
Rights
- Language dc:language
- en